COMMUNIQUÉS West-GlobeNewswire

-
Optimi Health Signs Psilocybin Supply Agreement With New Zealand-Based Mātai Medical Research Institute
09/04/2024 -
NeuroOne® Announces First Implant of OneRF™ Ablation Electrodes
09/04/2024 -
Nelk Boys to Partner With Safety Shot to Bring the Recovery & Wellness Drink to Fans and Followers
09/04/2024 -
Epic Bio Announces Robust Slate of Presentations at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting
09/04/2024 -
Scilex Holding Company Announces Launching of Co-Pay Programs for Both ZTlido® and ELYXYB® for Commercially Insured Patients and the addition of ELYXYB® to a Multi-State Medicaid Pharmaceutical Purchasing Group to Its Purchasing Pool
09/04/2024 -
Harvard Bioscience Announces Action to Improve Operational Efficiency and Support Ongoing Investments in Growth
09/04/2024 -
Verana Health to Reveal Results from Largest Pediatric Intraocular Lens Study, Funded by the FDA, During AAPOS 2024
09/04/2024 -
Privia Health to Report First Quarter 2024 Results on Thursday, May 9
09/04/2024 -
Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor
09/04/2024 -
Signati™ Medical Enrolls First Patient in Groundbreaking Sealed Vasectomy Procedure Trial
09/04/2024 -
Curium Announces First Commercial Dose in the Netherlands of PYLCLARI® – an Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer
09/04/2024 -
Virbac : Declaration of the number of shares and voting rights 03/2024
09/04/2024 -
Virbac : Déclaration d'actions et de droits de vote 03/2024
09/04/2024 -
Nanox Announces Collaboration with AhealthZ and SCL Science to Enter South Korean Market
09/04/2024 -
STRATA Skin Sciences Announces Renewal of Exclusive Distribution Agreements in China and Japan
09/04/2024 -
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma
09/04/2024 -
Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”
09/04/2024 -
Chromocell Issues Letter to Stockholders from Chief Executive Officer
09/04/2024 -
Allogene Therapeutics Announces Q2 Investor Conference Participation
09/04/2024
Pages